In this podcast episode, Miguel Regueiro, MD, discusses developing the medical home model for patients with IBD, technological advances for patients in GI and more.

• Intro :58
• The interview/about Regueiro 1:03
• Tell us about your family and where you grew up. 1:24
• How did you get interested in medicine? 2:16
• Who were your early influences? 4:18
• What is the medical home? 5:57
• How did you develop the idea to apply the medical home model to IBD? 7:45
• Did you get any funding from the payers for this model to keep costs under control for this patient population? 10:57
• Why hasn’t this model become standard of care for patients with complex IBD? 14:13
• What has worked, and what hasn’t worked when it comes to adopting an integrative care medical home model? 18:15
• Are there themes patients share as to why they wouldn’t want to be enrolled in a medical home? 21:28
• What motivated your change to go from UPMC to become the GI Chief of Cleveland Clinic? 23:09
• What have you learned in this position at Cleveland Clinic? 25:23
• Are you spending a lot of time on the business side of care as opposed to the patient side? 26:34
• How would you recommend that people prepare for having a position like this? 27:34
• Are you seeing a shift in excitement over taking on leadership roles outside of traditional academics? 30:02
• With our clinical tool chest changing so rapidly, is there a common theme that you use to guide the strategy of the institute on what to invest in? 35:06
• What are the challenges that you still see in the ways we are using telehealth? 39:05
• What are some of the most exciting things you see on the horizon in the realm of IBD management? 40:26
• Thank you, Miguel 42:55
• Thanks for listening 45:11

Miguel Regueiro, MD, is the chief of the Digestive Disease Institute at Cleveland Clinic, and professor in the department of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

We’d love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Regueiro, follow @MRegueiroMD on X.

Disclosures: Berry and Chey report no relevant financial disclosures. Regueiro reports being on the advisory boards of and consulting for Abavax, Abbvie, Amgen, Biocon, BMS, Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), Celgene, Celltrion, Gilead, Genentech, Johnson and Johnson, Lilly, Merck, Organon, Pfizer, Prometheus, Roche, Salix, Sanofi, Takeda and UBC.